ISDA

Deposition Date 2012-11-14

Release Date 2013-10-30

Last Version Date 2023-09-20

Entry Detail

PDB ID:

4HYU

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Crystal structure of JNK1 in complex with JIP1 peptide and 4-{4-[4-(3-Methanesulfonyl-propoxy)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexan

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.15 Å

R-Value Free:

0.26

R-Value Work:

0.22

R-Value Observed:

0.23

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Mitogen-activated protein kinase 8
Chain IDs:A
Chain Length:369
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P45983 Pfam ID:PF00069

Protein Blast

Polymer Type:polypeptide(L)
Molecule:C-Jun-amino-terminal kinase-interacting protein 1
Gene (Uniprot):MAPK8IP1
Chain IDs:B
Chain Length:11
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q9UQF2

Ligand Molecules

1BK

Primary Citation

Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.

Palmer, W.S, Alam, M, Arzeno, H.B, Chang, K.C, Dunn, J.P, Goldstein, D.M, Gong, L, Goyal, B, Hermann, J.C, Hogg, J.H, Hsieh, G, Jahangir, A, Janson, C, Jin, S, Ursula Kammlott, R, Kuglstatter, A, Lukacs, C, Michoud, C, Niu, L, Reuter, D.C, Shao, A, Silva, T, Trejo-Martin, T.A, Stein, K, Tan, Y.C, Tivitmahaisoon, P, Tran, P, Wagner, P, Weller, P, Wu, S.Y.Show

Bioorg.Med.Chem.Lett. 23 1486 1492 (2013)

PMID: 23352510 DOI: 10.1016/j.bmcl.2012.12.047

Abstact

A series of amino-pyrimidines was developed based upon an initial kinase cross-screening hit from a CDK2 program. Kinase profiling and structure-based drug design guided the optimization from the initial 1,2,3-benzotriazole hit to a potent and selective JNK inhibitor, compound 24f (JNK1 and 2 IC(50)=16 and 66 nM, respectively), with bioavailability in rats and suitable for further in vivo pharmacological evaluation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures